JP2020500875A5 - - Google Patents

Download PDF

Info

Publication number
JP2020500875A5
JP2020500875A5 JP2019529533A JP2019529533A JP2020500875A5 JP 2020500875 A5 JP2020500875 A5 JP 2020500875A5 JP 2019529533 A JP2019529533 A JP 2019529533A JP 2019529533 A JP2019529533 A JP 2019529533A JP 2020500875 A5 JP2020500875 A5 JP 2020500875A5
Authority
JP
Japan
Prior art keywords
polymorph
pyrido
hexahydro
isoquinoline
dimethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019529533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500875A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/064196 external-priority patent/WO2018102673A1/en
Publication of JP2020500875A publication Critical patent/JP2020500875A/ja
Publication of JP2020500875A5 publication Critical patent/JP2020500875A5/ja
Priority to JP2022189060A priority Critical patent/JP2023015405A/ja
Priority to JP2025010365A priority patent/JP2025071099A/ja
Withdrawn legal-status Critical Current

Links

JP2019529533A 2016-12-02 2017-12-01 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 Withdrawn JP2020500875A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022189060A JP2023015405A (ja) 2016-12-02 2022-11-28 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
JP2025010365A JP2025071099A (ja) 2016-12-02 2025-01-24 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662429652P 2016-12-02 2016-12-02
US62/429,652 2016-12-02
PCT/US2017/064196 WO2018102673A1 (en) 2016-12-02 2017-12-01 Use of valbenazine for treating schizophrenia or schizoaffective disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022189060A Division JP2023015405A (ja) 2016-12-02 2022-11-28 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用

Publications (2)

Publication Number Publication Date
JP2020500875A JP2020500875A (ja) 2020-01-16
JP2020500875A5 true JP2020500875A5 (enExample) 2022-04-08

Family

ID=60703209

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019529533A Withdrawn JP2020500875A (ja) 2016-12-02 2017-12-01 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
JP2022189060A Withdrawn JP2023015405A (ja) 2016-12-02 2022-11-28 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
JP2025010365A Pending JP2025071099A (ja) 2016-12-02 2025-01-24 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022189060A Withdrawn JP2023015405A (ja) 2016-12-02 2022-11-28 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
JP2025010365A Pending JP2025071099A (ja) 2016-12-02 2025-01-24 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用

Country Status (5)

Country Link
US (2) US20200078352A1 (enExample)
EP (2) EP4400171A3 (enExample)
JP (3) JP2020500875A (enExample)
TW (3) TW202345829A (enExample)
WO (1) WO2018102673A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL284874B2 (en) 2015-10-30 2023-10-01 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
LT3394057T (lt) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
KR20230169457A (ko) 2017-01-27 2023-12-15 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
RS66714B1 (sr) 2017-09-21 2025-05-30 Neurocrine Biosciences Inc Formulacija visoke doze valbenazina i sastavi, postupci i kompleti povezani sa njim
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
MX2020003421A (es) 2017-10-10 2020-07-20 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
EP3733666B1 (en) 2017-12-26 2022-09-21 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof
EP3806856A1 (en) * 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
CN110818705A (zh) * 2018-08-14 2020-02-21 苏州鹏旭医药科技有限公司 缬苯那嗪的盐型和相应晶型与其制备方法
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN112933055B (zh) * 2021-03-23 2023-01-13 安徽九华华源药业有限公司 帕利哌酮胃滞留片及其制备方法
CA3220946A1 (en) * 2021-06-30 2023-01-05 Angel S. Angelov Valbenazine for use in the add-on treatment of schizophrenia
EP4387679A1 (en) 2021-08-20 2024-06-26 Neurocrine Biosciences, Inc. Methods of screening for vmat2 inhibitors

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
ZA9711385B (en) 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
MXPA03001771A (es) 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
ATE415968T1 (de) * 2005-08-06 2008-12-15 Cambridge Lab Ireland Ltd 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
CA2736409C (en) 2008-09-18 2017-07-11 Auspex Pharmaceutical, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
ES2731228T3 (es) * 2009-01-20 2019-11-14 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Acido benzoico o sales del mismo para mejorar la actividad de un producto farmacéutico
JP2013501810A (ja) 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
IT1399315B1 (it) * 2010-04-08 2013-04-16 Cappelli Procedimento per disporre su una qualsiasi superficie verniciabile, dei circuiti conduttori e/o generatori di cariche elettriche e circuiti realizzati con tale procedimento.
CA2883641C (en) 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CA3148303C (en) * 2013-12-03 2024-02-27 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carboline compounds for use in treatment of bipolar disorders
CA2938581C (en) * 2014-02-07 2023-02-28 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
HUE057839T2 (hu) * 2014-05-06 2022-06-28 Neurocrine Biosciences Inc Valbenazin adagolási rendje hiperkinetikus mozgás-zavarok kezelésére
WO2016210180A2 (en) * 2015-06-23 2016-12-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
IL284874B2 (en) * 2015-10-30 2023-10-01 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof

Similar Documents

Publication Publication Date Title
Romagnolo et al. Cardiovascular autonomic neuropathy and falls in Parkinson disease: a prospective cohort study
Williams Asthma and pregnancy
WO2011020061A2 (en) Compositions and methods of for treating bipolar disorder
JP2009530234A5 (enExample)
TW202142229A (zh) 治療雷葛氏症候群之病患的方法
CN115518057A (zh) 莰醇在制备治疗缺血性脑卒中的药物中的用途
CN116419746A (zh) 右旋普拉克索用于治疗中度至重度哮喘的用途
JP2010513250A5 (enExample)
Wang et al. Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: a randomized, double-blind, placebo-controlled trial
Vatlach et al. Safety profile comparison between extemporaneous and a licensed preparation of caffeine citrate in preterm infants with apnea of prematurity
JP2022512584A5 (enExample)
O’Connor et al. Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma
JP2021517128A5 (enExample)
Teng et al. Ptosis as the initial presentation of Guillain-Barré syndrome
Yaroslav et al. Amnesia After the Hemorrhagic and Ischemic Stroke: is IT Possible to Minimize Its Development Already in Intensive Care?
CN108014106A (zh) 卡格列净在制备用于辅助治疗特发性肺纤维化的药物中的应用
Prenner et al. Safety of desloratadine syrup in children six months to younger than 2 years of age: a randomized, double-blinded, placebo-controlled study
CN110538178A (zh) 氢溴酸樟柳碱在制备治疗脑小血管病相关认知功能障碍的药物中的用途
Gomez-Bernal et al. Vitamin B12 deficiency manifested as mania: a case report
Mahesh Role of Ayurvedic Medicines and Leech Therapy In management of Buerger’s Diseases–A Case Report
TWI883819B (zh) 組合物用於製備改善認知能力之藥物的用途
Rajanandh et al. Does dose reduction of an inhaled corticosteroid with the addition of leukotriene antagonist is clinical significance in asthma patients
CN120754183A (zh) 一种用于缓解慢性阻塞性肺疾病急性加重期黏液高分泌的苏半苓橘汤及其制备方法和应用
Bareille et al. Efficacy of a new selective steroid (GW870086) in asthma: an adaptive, randomised, controlled trial
Blay et al. A case of obsessive-compulsive disorder responding to duloxetine